Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 1 institution in 1 country.
Nereida Jiménez de OyaDepartment of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain.ORCID 0000-0003-3129-813X
Patricia PérezCentro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain.
Ana-Belén BlázquezDepartment of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain.ORCID 0000-0002-0847-0977
Estela Escribano-RomeroDepartment of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain.ORCID 0000-0002-5036-7607
Mariano EstebanCentro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain.ORCID 0000-0003-0846-2827
Juan-Carlos SaizDepartment of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain.ORCID 0000-0001-8269-5544
Juan García-ArriazaCentro Nacional de Biotecnología (CNB), Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain.ORCID 0000-0002-5167-5724
Miguel A Martín-AcebesDepartment of Biotechnology, Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA), Consejo Superior de Investigaciones Científicas (CSIC), 28040 Madrid, Spain.ORCID 0000-0001-6015-3613
Consejo Superior de Investigaciones Científicas · ES
Funding
Comunidad de Madrid P2018/BAA-4370 PLATESA2-CMMinisterio de Ciencia e Innovación, Agencia Estatal de Investigación MCIN/ AEI / 10.13039/501100011033 E-RTA-2017-00003-C03Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación MCIN/ AEI / 10.13039/501100011033 PID2019-105117RR-C21Ministerio de Ciencia e Innovación, Agencia Estatal de Investigación MCIN/ AEI / 10.13039/501100011033 PID2020-11919JRJ-100Ministerio de Economía y Competitividad SAF2013-45232-RMinisterio de Economía y Competitividad SAF2017-88089-R
6 · The paper itself
Abstract
Zika virus (ZIKV) is a mosquito-borne flavivirus whose infection in pregnant women is associated with a spectrum of birth defects, which are together referred as Congenital Zika Syndrome. In addition, ZIKV can also induce Guillain-Barré syndrome, which is an autoimmune disease with neurological symptoms. The recent description of the first local infections of ZIKV in the European continent together with the expansion of one of its potential vectors, the Asian tiger mosquito
Indexed as
antibody-dependent enhancement of infectioncross-protectionimmunogenicityMVAvaccinevaccine safetyWest Nile virusZika virus
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Low Immune Cross-Reactivity between West Nile Virus and a Zika Virus Vaccine Based on Modified Vaccinia Virus Ankara. · full record | OpenQuestion